Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 21;7:8360. doi: 10.1038/s41598-017-08641-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

In vivo PK profile and tumor growth inhibition bioactivity of the BsAb (CD3×HER2). (a) In vivo PK analysis of the BsAb and trastuzumab in Balb/c mice (N = 5). Single i.p. doses of 5 mg/kg BsAb or trastuzumab were injected into Balb/c mice. Test animals’ serum samples were assayed by ELISA. (b) PK parameters of trastuzumab and the BsAb. Data fitted to the non-compartmental analysis model. (c) BsAb inhibited growth of subcutaneously transplanted NCI-N87 cell. NCI-N87 cells were injected together with unstimulated human PBMCs from healthy donors. Mice (N = 8) were treated with 0.33 mg/kg, 1 mg/kg and 3 mg/kg i.p. dose of the BsAb and 1.5 mg/kg dose of Trastuzumab once a week. (d) Photographs of excised tumors at the end of the experiment. Error bar, SEM.